Donor-Derived CD7 CAR T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donor-Derived CD7 CAR T Cells, covering 2025-05-18 to 2025-05-18. Get the full timeline:
Most recent: Clinical Trial Update: Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma [Phase 2]